Biopharmaceutical company CorMedix Inc. (CRMD) announced Thursday the appointment of Joseph Todisco as Chief Executive Officer of the company. Todisco also will join the CorMedix Board of Directors. The company expects Todisco to join CorMedix on May 16 or such earlier date as he completes his contractual responsibilities to his current employer.
Todisco is an experienced pharmaceutical industry leader with a track record of building businesses globally and providing commercial leadership over the last 20 years. Previously, he was a senior executive at Amneal Pharmaceuticals, where for the past 11 years he has held various roles, most recently as Executive Vice President, Chief Commercial Officer.
During his tenure at Amneal, Todisco held roles overseeing corporate development and international operations, leading commercial teams in several international markets including the UK, Australia and Germany, as well as leading Amneal's merger integration with Impax Laboratories in 2018.
Todisco was previously Co-Founder and managing executive of Gemini Laboratories.
Prior to joining Amneal, Todisco was Vice President, Business Development & Licensing at Ranbaxy, Inc. Prior to Ranbaxy, he held various roles at Par Pharmaceutical, and in his earlier career held positions at Oppenheimer & Co. and Marsh & McLennan Cos.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.